Systematic multi-omics study based on tumor tissue and blood of pancreatic cancer patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000037215

Enrollment

Unknown

Registered

2020-08-27

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Group of pancreatic cancer:nil

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Have undergone radical resection of pancreatic cancer; 2. No serious underlying diseases; 3. Have not undergone radiotherapy or chemotherapy before; 4. Pathologically diagnosed as pancreatic cancer or chronic pancreatitis; 5. No significant disfunction of heart, lung, or kidney and no HIV or syphilis infection; 6. All patients or blood donation volunteers should sign an informed consent form when selected.

Exclusion criteria

Exclusion criteria: 1. The general condition of pancreatic cancer patients before surgery is poor, and it is estimated that they cannot tolerate surgery, postoperative chemotherapy and targeted therapy; 2. Patients with metastases; unstable angina, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, prolonged QT interval (>450ms); 3. Malignant tumors in other parts appeared within the last 5 years; 4. The patient cannot be followed up or is participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Proteomics;	—

Secondary

Measure	Time frame
Genomics;Transcriptomics;Metabolomics;	—

Countries

China

Contacts

Public ContactGang Jin

Shanghai Changhai Hospital

jingang@sohu.com+86 02131161628

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026